Evolus Inc (EOLS)vsViatris Inc (VTRS)
EOLS
Evolus Inc
$7.64
+3.60%
HEALTHCARE · Cap: $488.77M
VTRS
Viatris Inc
$18.77
+0.27%
HEALTHCARE · Cap: $21.43B
Smart Verdict
WallStSmart Research — data-driven comparison
Viatris Inc generates 4557% more annual revenue ($14.74B vs $316.49M). VTRS leads profitability with a -2.8% profit margin vs -10.8%. VTRS earns a higher WallStSmart Score of 48/100 (D+).
EOLS
Avoid34
out of 100
Grade: F
VTRS
Hold48
out of 100
Grade: D+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+70.5%
Fair Value
$14.59
Current Price
$7.63
$6.96 discount
Margin of Safety
-82.5%
Fair Value
$8.84
Current Price
$18.77
$9.93 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Revenue surging 21.2% year-over-year
Reasonable price relative to book value
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -18730.0% — below average capital efficiency
4.9% revenue growth
ROE of -2.9% — below average capital efficiency
Earnings declined 70.6%
Distress zone — elevated risk
Comparative Analysis Report
WallStSmart ResearchBull Case : EOLS
The strongest argument for EOLS centers on Debt/Equity, Revenue Growth. Revenue growth of 21.2% demonstrates continued momentum.
Bull Case : VTRS
The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.
Bear Case : EOLS
The primary concerns for EOLS are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : VTRS
The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.
Key Dynamics to Monitor
EOLS profiles as a growth stock while VTRS is a turnaround play — different risk/reward profiles.
EOLS carries more volatility with a beta of 1.34 — expect wider price swings.
EOLS is growing revenue faster at 21.2% — sustainability is the question.
VTRS generates stronger free cash flow (329M), providing more financial flexibility.
Bottom Line
VTRS scores higher overall (48/100 vs 34/100). EOLS offers better value entry with a 70.5% margin of safety. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Evolus Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Evolus, Inc., a high-performance beauty company, provides aesthetic medical products for physicians and their patients in the United States. The company is headquartered in Newport Beach, California.
Viatris Inc
HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA
Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.
Visit Website →Compare with Other DRUG MANUFACTURERS - SPECIALTY & GENERIC Stocks
Want to dig deeper into these stocks?